MedTrace Logo

Postbiotics Ameliorate Cachexia in Patients With Non-small-cell Lung Cancer

NCT07185308 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-09-25

No results posted yet for this study

Summary

This study aims to evaluate the efficacy of the oral postbiotic preparation JK-5G in improving body weight among patients with non-small-cell lung cancer (NSCLC)-related cachexia. By means of a randomized controlled trial, we will compare the between-group difference in body-weight changes between the JK-5G and placebo arms to clarify its nutritional therapeutic benefit.

Conditions

  • Cachexia; Cancer

Interventions

DIETARY_SUPPLEMENT

Postbiotics, 2.5 g per dose, three times per day

Postbiotics oral powder, 2.5 g per dose, administered three times daily for a total duration of 90 days (four 21-day chemotherapy cycles).

DIETARY_SUPPLEMENT

Placebo, 2.5 g per dose, three times per day

Placebo made of cyclodextrine, oral powder, 2.5 g per dose, administered three times daily for a total duration of 90 days (four 21-day chemotherapy cycles).

Sponsors & Collaborators

  • First Affiliated Hospital of Wenzhou Medical University

    collaborator OTHER

  • The First Hospital of Jilin University

    collaborator OTHER

  • Fujian Cancer Hospital

    collaborator OTHER_GOV

  • Zhongnan Hospital

    collaborator OTHER

  • National Cancer Center/National Cancer Clinical Medical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    collaborator UNKNOWN

  • Affiliated Hospital of Jiangnan University

    collaborator OTHER

  • Jiangsu Provincial People's Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Henan University

    collaborator UNKNOWN

  • Shanghai Changzheng Hospital

    collaborator OTHER

  • Zhengzhou University

    collaborator OTHER

  • Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

    lead OTHER

Principal Investigators

  • Hongxia Xu · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07185308 on ClinicalTrials.gov